Fig. 1
From: A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
Subject flow. Patient withdrawals during dose-escalation (POM-001) and dose-extension (POM-002) were by physician decision and subject decision, respectively